The prognostic values of TAZ mRNA expression in gastric cancer
According to Kaplan-Meier plotter, up-regulated TAZ mRNA expression was negative associated with Overall, Post-progression and First progression survival rates of gastric cancer patients(Fig. 1A, p < 0.05). As shown in Table I, high mRNA expression of TAZ was relationship with worse OS of gastric cancer patients, even stratified by tumor(topography) status, metastasisin status, treatment, and her2 positivity. It has the same result in male patients of stage II, stage III, stage IV, N1-3, N1, N2, N3, perforation none, poor-differentiated, diffuse type(p < 0.05). The Post-progression survival rate of the gastric cancer patients were associated with worse prognosis in patients, even stratified by gender, lymph node status, metastasisin status, lauren’s classification, her2 positivity. It had the same result in patients with stage II, stage III, stage IV, T2, T3, surgery alone, other adjuvant. The First progression survival rate of the gastric cancer patients were associated with worse prognosis, even stratified into gender, treatment. It also had the same result in patients of stage II, stage III, T2, T3, M0, none-perforation, intestinal or diffuse-type, and her2 negative. According to DErrico’s datasets, we found that the expression of TAZ mRNA was higher in gastric adenocarcinoma(including mixed and diffuse-type) than gastric mucosa(Fig. 1B, p < 0.05). Cho’s datasets shown that TAZ mRNA expression was higher in gastric cancers than gastric tissue, even stratified into intestinal and mixed-type adenocarcinoma(Fig. 1B, p < 0.05). Wang’s, Chen’s and Cui’s datasets also shown the same results(Fig. 1B, p < 0.05). Univariate analysis showed that age, TNM staging, lymph node metastasis, distant metastasis was correlated with prognosis in patients with gastric cancer(Table III, p༜0.05). COX multivariate analysis showed that age and distant metastasis are risk factors affecting the survival of patients with gastric cancer(Table IV, p༜0.05).
The prognostic values of YAP mRNA expression in gastric cancer
In Kaplan-Meier plotter, higher YAP mRNA expression was negative associated with Overall, Post-progression and First progression survival rates of gastric cancer patients(Fig. 2A, p < 0.05). As shown in the study, high mRNA expression of YAP was negatively related with male patients with OS, T2, T3, N1-3, N2, M0, surgery alone, diffuse-type, or Her2 negative(Table II, p < 0.05). We found that a higher YAP mRNA expression was negatively associated with Post-progression survival rates of gastric cancer patients, even stratified by gender and Her2 positivity. It was also the same result for the gastric cancer patients with stage II-IV, T2, T3, M0, surgery alone, or intestinal-type. The First progression survival rate of the gastric cancer patients were associated with worse prognosis in male, stage III-IV, T2, N1-3, N3, M0, urgery alone, intestinal-type, or Her2 negative(Table II, p < 0.05). According to Cho’s, we found that the expression of YAP mRNA was higher in gastric adenocarcinoma than gastric tissue, even stratified into intestinal, diffuse and mixed-type adenocarcinoma(Fig. 2B, p < 0.05). Chen’s datasets also shown that YAP mRNA expression was higher in gastric adenocarcinoma than gastric mucosa, even stratified into intestinal, diffuse and mixed-type adenocarcinoma(Fig. 2B, p < 0.05). Wang’s and Cui’s datasets shown that YAP mRNA expression was higher in gastric cancer than gastric mucosa and gastric tissue(Fig. B, p < 0.05). Derrico’s datasets also shown that YAP mRNA expression was higher in gastric ntestinal type adenocarcinoma than gastric mucosa(Fig. 2B, p < 0.05). univariate analysis showed that age, TNM staging, lymph node metastasis, distant metastasis was correlated with prognosis in patients with gastric cancer(Table III, p༜0.05). COX multivariate analysis showed that age, sex and distant metastasis are risk factors affecting the survival of patients with gastric cancer(Table IV, p༜0.05).